Effect of Finerenone in IgA Nephropathy

Summary

The aim of this trial is to conduct a randomized, multicenter, placebo-controlled, double-blind clinical trial to determine the safety and efficacy of Finerenone in reducing proteinuria and protecting renal function in patients with IgA nephropathy. The primary endpoint event was the change in urinary albumin/creatinine ratio between the two groups at 12 months of treatment.

Timeline

Start

2024-10-08

Primary completion

2026-06-08

Completion

2026-10-08

Drugs

Indications